 |
 |
 |
 |
 |
 |
 |
|
 |
 |
Press ReleasesGenstruct Presents its Causal Mechanisms for Prostate Carcinoma at the Drug Discovery Technology World CongressCambridge, Mass. — August 10, 2004 — Genstruct Inc., a knowledge-driven discovery company, will present findings from one of its independent discovery programs at IBC Life Sciences’ 9th Annual Drug Discovery Technology World Congress being held August 8-13 in Boston. Dexter Pratt, project leader for Genstruct’s Oncology Program, will outline the program’s findings describing both probable molecular causes and mechanisms involved in androgen-dependent prostate carcinoma. To define the molecular causes of prostate carcinoma, Genstruct has utilized its Molecular EpistemicsTM discovery platform to build and interrogate an Oncology Knowledge AssemblyTM model using computer-aided causal reasoning. The model includes the knowledge of cell cycle, cell signaling, vesicle trafficking, metabolism, and gene regulation. It is the largest and most complete computable model of prostate carcinoma ever assembled. The findings show the utility of causal reasoning models for hypotheses generation, and demonstrate a powerful new approach to systems biology and drug discovery. "We are focused on pioneering new approaches to better understand and treat complex disease," said Keith O. Elliston, Ph.D., president and CEO of Genstruct. "Dexter’s presentation will demonstrate one area in which our novel Molecular Epistemics platform is used to build comprehensive computable models to overcome the cognitive barriers hindering critical path research. With more than 200,000 new cases of prostate carcinoma to be diagnosed this year alone, we believe our efforts to identify underlying biological mechanisms and develop unique therapeutics in this area are critical to improving the outcome for patients. Genstruct’s Molecular Epistemics platform enables the development of logical models of biological systems that uncover and define compound mechanisms of action and disease mechanisms. The company has ongoing research programs in prostate cancer and type 2 diabetes mellitus, and is focused primarily on the disease areas of oncology, metabolic disorders, and inflammation. The company believes that the identification of mechanisms and biomarkers in these areas will ultimately lead to improved leads, optimal clinical trial design and execution, and faster FDA product approval. About Genstruct Genstruct is a knowledge-driven discovery company focused on pioneering new approaches to the understanding and treatment of complex diseases (i.e. oncology, metabolic disorders, inflammation). Genstruct has developed a platform for the discovery of compound mechanisms of action (MOA) and biomarkers called Molecular EpistemicsTM . The platform comprises a suite of patent-pending technologies that model and analyze compound MOA: the Knowledge AssemblyTM process which enables rapid, ongoing construction of an addressable biological knowledgebase; and a flexible system for mining and refining the knowledgebase, the Epistemics EngineTM system for mechanism discovery and validation. Genstruct engages in discovery and development partnerships that apply the Molecular Epistemics platform to accelerate and increase the output of drug discovery and development programs. The Company was founded in 2001 by a team including Flagship Ventures, and is based in Cambridge, Mass. For more information please visit www.genstruct.com. Contact: Karen Higgins A & E Communications for Genstruct (610) 831-5723 khiggins@aandecomm.com Return to Press Releases |
 |
|
 |
| One Alewife Center | Cambridge, MA 02140 | (617) 547-5421 | sitemap |